Lipocine director Jeffrey Fink to resign effective Jan. 1, 2026
Lipocine Inc. reported that board member Jeffrey Fink has informed the Board of Directors that he will resign from the board effective January 1, 2026, for personal reasons.
Rhea-AI Filing Summary
Lipocine Inc. reported that board member Jeffrey Fink has informed the Board of Directors that he will resign from the board effective January 1, 2026, for personal reasons. The company states that his resignation is not the result of any disagreement with the company on any matter, which suggests no underlying dispute or conflict is driving the change. The board plans to conduct a search for a new director to fill the upcoming vacancy.
Positive
- None.
Negative
- None.
8-K Event Classification
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did Lipocine (LPCN) disclose?
Lipocine disclosed that Jeffrey Fink, a member of its Board of Directors, informed the board that he will resign effective January 1, 2026.
Why is Lipocine director Jeffrey Fink resigning?
The company states that Jeffrey Fink is resigning from the board for personal reasons, effective January 1, 2026.
How will Lipocine (LPCN) handle the board vacancy after Fink’s resignation?
The Board of Directors intends to conduct a search for a new director to replace Jeffrey Fink following his resignation.
When does Jeffrey Fink’s resignation from Lipocine’s board become effective?
His resignation from Lipocine’s Board of Directors becomes effective January 1, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
Commission
File No.
(State or other jurisdiction of incorporation) |
(IRS Employer Identification Number) |
(Address of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
Former name or former address, if changed since last report: Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offices |
(b) On December 12, 2025, Jeffrey Fink informed the Board of Directors (the “Board”) of Lipocine Inc. (the “Company”) that he will resign from the Board effective January 1, 2026 for personal reasons. The Board intends to conduct a search for a new director. Mr. Fink’s resignation was not the result of any disagreement with the Company on any matter.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: December 15, 2025 | LIPOCINE INC. | |
| By: | /s/ Mahesh V. Patel | |
| Name: | Mahesh V. Patel | |
| Title: | President and Chief Executive Officer | |